



BRIDGING THE GAP

Advancing Prostate Cancer Care in Egypt

EXECUTIVE SUMMARY

Egypt is making gradual progress in prostate cancer care, with increasing diagnostic capacity in urban centers and some access to treatment through public hospitals. However, significant gaps remain in early detection, equitable service distribution, and integration of advanced therapies. While screening and treatment are more available than in Level 1 countries, geographic disparities, limited biomarker testing, and inconsistencies in clinical practice hinder optimal outcomes.


This policy brief assesses Egypt's current prostate cancer landscape and outlines reforms to strengthen its **Level 2 – Developing** maturity toward a more equitable, standardized system.

INTRODUCTION

Building on Treatment Availability Amid Unequal Access

Prostate cancer is among the top cancers affecting Egyptian men, with incidence rising alongside improved awareness of male health issues. National cancer control initiatives have expanded oncology infrastructure, particularly in Cairo and Alexandria, but services remain concentrated in major cities.

Most patients in rural areas face travel burdens and delays, and opportunistic rather than organized screening continues to result in late-stage diagnosis. Egypt's **Level 2 – Developing** maturity provides a platform for scaling up national guidelines, decentralizing services, and improving affordability for advanced care.



Egypt Ranks at Level 2 – Developing Prostate Cancer Maturity Framework



PROSTATE CANCER IN EGYPT


Current Landscape and Strategic Gaps

Pillar	Current Status	Strength	Policy Action
Early Detection & Diagnosis	PSA testing and DRE available in urban public and private hospitals; no organized national screening program. Most cases still detected at Stage II–III.	Expanding diagnostic services in regional cancer centers.	Launch a national screening strategy targeting men aged 50+ and high-risk groups; strengthen referral pathways from primary to tertiary care.
Biomarker & Molecular Testing	Limited biomarker testing in public sector; more available in private settings. Not routinely reimbursed.	Availability in some university hospitals and private labs.	Integrate biomarker testing into public services; negotiate with suppliers for cost reductions.
Treatment Access	Surgical and radiotherapy services available in major cities; limited in rural areas. Hormonal therapy & chemotherapy accessible but may incur out-of-pocket costs.	Large oncology institutions such as the National Cancer Institute offer multi-modality care.	Expand regional radiotherapy facilities; include advanced hormonal therapies in full public insurance coverage.
Clinical Guidelines	No unified national prostate cancer treatment protocol; variation in practices across facilities.	Academic and specialist centers follow adapted international guidelines.	Develop and implement standardized national treatment guidelines; ensure dissemination and training.
Palliative & Survivorship Care	Palliative services available in some cancer centers but uneven across the country; community outreach is limited.	Growing NGO involvement in palliative support.	Expand palliative care teams to all governorates; integrate survivorship care plans into cancer follow-up protocols.



CONCLUSION & Call to Action

Egypt's **Level 2 – Developing** maturity reflects a health system with significant capacity in urban centers but persistent inequities across regions. Early detection remains insufficient, and advanced therapies are out of reach for many patients without private insurance. Strengthening national coordination, decentralizing services, and improving affordability will be key to advancing toward higher maturity levels.



CONCLUSION

Egypt stands at a pivotal point in its prostate cancer care development. While more advanced than Level 1 systems, its current framework remains hindered by fragmented screening approaches, centralization of advanced care, and affordability challenges. By decentralizing infrastructure, improving guideline adherence, and ensuring equitable access to both diagnostics and therapies, Egypt can move toward a fully integrated, patient-focused system that improves survival rates and quality of life for men across the country.